$MDT (Medtronics) earnings were better than expected, however a review of the earnings report does not change our medium term thesis. Unless our methodology tells us otherwise, we will use spikes up to add to our short position. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD
We have been short on $MDT (Medtronics) with the first scale in at $36.20 and more aggressive entry at $38.00. $BSX earnings show weakness in both stents and implantable cardiac devices. Going forward guidance for US is quite a bit lower than expected. This confirms our thesis and we will
Consider start scaling in a short position in MDT right here at $36.20. MDT had passed all of our screens for a short sale, but we had been waiting for a trigger that the market pays attention to before entering the trade. Patience in entering short sales is especially important